Tag: bamlanivimab
SARS-CoV-2 coronavirus variants B.1.351 and P.1 escape from neutralizing antibodies
“In contrast, entry of the B.1.351 and P.1 variant was partially (Casirivimab) or fully (Bamlanivimab) resistant to antibodies used for COVID-19 treatment. More...
U.S. halts distribution of Eli Lilly’s coronavirus antibody treatment bamlanivimab as a monotherapy
The U.S. government has halted distribution of Eli Lilly’s COVID-19 antibody treatment bamlanivimab (LY-CoV555) as a monotherapy just four months after it received FDA emergency use authorization, citing a sustained increase in variants of SARS-CoV-2 that are resistant to the monotherapy. More...